more

Sarepta Therapeutics (SRPT)

(Delayed Data from NSDQ)

$133.34 USD

+0.26 (0.20%)

Updated Aug 15, 2024 04:00 PM ET

After-Market: $133.39 +0.05 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.03%
2	Buy	17.70%
3	Hold	9.37%
4	Sell	5.03%
5	Strong Sell	2.48%
S&P	500	11.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum D VGM

Industry Rank:

Top 32% (80 out of 251)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why

by Zacks Equity Research Published on January 16,2024

Adaptimmune (ADAP) surges on the completion of the rolling submission, with the FDA seeking approval for its most advanced pipeline candidate as the first engineered cell therapy for solid tumors.

Iovance (IOVA) Surges More Than 150% in 3 Months: Here's Why

by Zacks Equity Research Published on January 15,2024

Iovance's (IOVA) surges on the anticipated FDA approval for its lead pipeline drug as the first individualized, one-time cell therapy for certain patients with melanoma.

Vir Biotechnology (VIR) Gains 21.7% in 3 Months: Here's Why

by Zacks Equity Research Published on January 15,2024

After a major pipeline setback, Vir Biotechnology (VIR) stock gains 21.7% in three months on its restructuring plan to cut operating expenses.

Solid Biosciences (SLDB) Rises 271% in 3 Months: Here's Why

by Zacks Equity Research Published on January 15,2024

The FDA's recent clearance of Solid Biosciences' (SLDB) investigational new drug application on SGT-003 for treating Duchenne muscular dystrophy pushes the stock higher.

biotechs

Emergent (EBS) Gets $235.8M DoD Contract for Anthrax Vaccine

by Zacks Equity Research Published on January 12,2024

Emergent (EBS) signs a deal with the U.S. Department of Defense to supply its anthrax vaccine initially for a five-year period, with an option to extend it for another five years.